Antiviral Drugs on the Treatment of SARS-CoV-2

A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04727775

Acronym

FavRem

Enrollment

150

Registered

2021-01-27

Start date

2020-12-01

Completion date

2023-07-25

Last updated

2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complication of Medical Care, Pneumonia, Viral

Brief summary

Retrospective Non-Randomized Analytical Cohort Study of Completed SARS-CoV2 COVID19 Cases

Detailed description

Analyzing the case histories of patients with SARS-CoV2 COVID19 infection and the impact on the outcomes of prescribing antiviral drugs

Interventions

DRUGFavipiravir

Antiviral drugs

DRUGRemdesivir

Antiviral drugs

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

main group * Patients with COVID19 with medium and easy condition disease * take favipiravir/remdisivir control group * Patients with COVID19 with medium and easy condition disease * not take favipiravir/remdisivir

Exclusion criteria

* patients younger 18 * severe conditionis

Design outcomes

Primary

Measure	Time frame	Description
Outcome without comlications	14 days	The recovery time will be evaluated with and without antiviral drugs retrospectively in homogeneous groups of patients with SARS-CoV2

Secondary

Measure	Time frame	Description
Heart rate	14 days	Measure
SpO2	14 days	Measure
Blood pressure	14 days	Measure
Respiratory rate	14 days	Measure

Countries

Kazakhstan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026